anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the US about 1/3 of college women show evidence of HPV infection. The clinical problem may be even larger in developing countries. There are currently no effective therapies for HPV infections, aside from therapeutic cone biopsies, which often are followed by recurrent, progressive lesions. Thus, pharmaceutical compositions and processes for treatment of an HPV infection are detailed. In particular, a pharmaceutical composition for inhibiting growth of a human papilloma virus-infected cell is provided which includes a peptide halomethyl ketone inhibitor of a chymotrypsin or chymotrypsin-like protease and a pharmaceutically acceptable carrier. A preferred inhibitor is AAPFcmk.
BACKGROUND: Effective vaccines for the prevention of cervical cancers are available in India. The existing knowledge and attitude regarding the Human Papillomavirus (HPV) vaccine varies widely among available studies. Our study aimed to estimate pooled prevalence related to knowledge, attitude, and practice of HPV vaccination in India.
METHODOLOGY: We conducted systematic searches in PUBMED, EMBASE, CINHAL, PROQUEST, and Cochrane Library databases using database-specific search strategies. The random effects model was used for estimating the pooled proportion of knowledge, attitude, and practice. The outlier studies were identified using the Baujat test. Egger's regression test and funnel plots were used to identify publication bias.
RESULTS: Database-specific search strategies yielded 2,377 records from five databases. We identified 48 studies for full-text retrieval after screening titles and abstracts. Finally, 27 studies were included in the meta-analysis. The pooled prevalence of knowledge regarding HPV vaccines in India was 0.22 (CI;0.14-0.31, I2 =99.5%). The pooled prevalence of positive attitudes towards the uptake of HPV vaccines in India was 0.45 (CI;0.33-0.57, I2 =100%). The pooled prevalence of coverage of HPV vaccines in India was 0.04 (CI;0.02-0.07, I2 =96%). Significant publication bias was present for the studies' reported knowledge and coverage.
CONCLUSION: The knowledge, attitude, and coverage of the HPV vaccine were low in India. It suggests effective strategies to improve knowledge and attitudes towards HPV vaccination in India.
To transmit a message also to a patient who does not use a portable terminal.SOLUTION: A management server transmits a message for patients of a hospital to a portable terminal. The management server includes a server storage unit, a server third communication unit, and a server control unit. The server storage unit stores first identification information in association with one or more pieces of second identification information for uniquely identifying a patient. The first identification information is information for uniquely identifying a portable terminal or information for uniquely identifying a user of an application installed on the portable terminal. The server third communication unit transmits a message to a portable terminal corresponding to the first identification information. When multiple pieces of second identification information are associated with the same first identification information, the server control unit controls the server third communication unit so that messages for patients corresponding to the second identification information are displayed on the portable terminal corresponding to the same first identification information.SELECTED DRAWING: Figure 4
Pre-diabetic state is aphase of impaired glucose tolerance 2 hours Postprandial Glucose (PG) in 75 g oral glucose tolerance test 140 mg/dL-199 mg/dL and/or impaired fasting glucose 100 mg/dL-125 mg/dL and/or HbA1c 5.7-6.4% \[5\]. Pre-diabetes is pathophysiologically similar to Type II Diabetes with basic defect being insulin resistance and early beta cell failure. The amplitude of large pulses and the rapid oscillations of insulin secretion are lost in pre-diabetes. In pre-diabetes, the glycaemic excursions are usually lower than normaland there is a delay and prolongation in the second phase of insulin secretion \[6\]. Recent studies have shown that colonisation with H.pylori is associated with increased development of diabetes mellitus \[7-11\]. A step towards identifying treatable causes of diabetes mellitus will aid the medical health system in developing new strategies in preventing the progression of pre-diabetes to overt diabetes mellitus .Dyslipidemia is a complex disease and a major risk factor foradverse cardiovascular events \[12\]. High levels of Low Density Lipoproteins (LDL) and low levels of High Density Lipoprotein (HDL) are associated with increased incidence of stoke and myocardial infarction \[13\]. dyslipidemia also plays a major role in macrovascular complications of Diabetes \[14\]. There is increasing evidence for the role of H.pylori infection in the initiation, development or persistence of atherosclerosis and coronary heart disease \[15,16\]. Therefore, exploring the role of treatable causes of dyslipidemia like H.pylorimay help in preventing the progression of dyslipidemia and its adverse effects.The present study aimed to assess the possible role of H.pylori infection on diabetic profile and lipid profile in pre-diabetic patients.
OBJECTIVES: To compare the differences in antibiotic use between COPD and non-COPD residents, and to explore the effect of COPD on antibiotic use.
METHODS: Participants aged 40 years old or over from the Songjiang Adult Cohort were included. Information on prescription and baseline survey was collected based on the health information system. A logit-negative binomial Hurdle model was used to explore correlations between COPD and percentage of antibiotic use and average rate of antibiotic prescribing of different types of antibiotic. Multinomial logistic regression was used to assess the association between COPD and antimicrobial combination therapy and routes of administration.
RESULTS: A total of 34576 individuals were included and 1594 (4.6%) were COPD patients. During the 6 years' follow-up, the percentage of antibiotic use for COPD patients was 98.4%, which was 7.88 (95%CI: 5.24-11.85) times of that for non-COPD patients after adjusting for potential confounders. The prescribing rate was 3220 prescriptions (95%CI: 3063.6-3385.2) per 1000 person-years for COPD patients, which was 1.96 (95%CI: 1.87-2.06) times of that for non-COPD patients. Other beta-lactam antibacterials, Macrolides, lincosamides and streptogramins, and quinolone antibacterials were the most commonly used types of antibiotic. Except for aminoglycoside antibacterials, both percentage of antibiotic use and rate of antibiotic prescription were increased in COPD patients. COPD patients were more likely to be prescribed a maximum of two antibiotics (OR=1.34, 95%CI: 1.20-1.50); and were more likely to use antibiotics intravenously (OR=2.77, 95%CI: 2.47-3.11).
CONCLUSION: COPD patients were more likely to have increased antibiotic use in a large-scale population-based adult cohort, suggesting COPD patients are a high-priority group for the management of antibiotic use in communities.
<P>PROBLEM TO BE SOLVED: To provide fermented papaya product-containing soap containing a fermented papaya product that has high hydroxyl radical-erasing activity and also has singlet oxygen-erasing activity.  <P>SOLUTION: Glucose, lactic acid bacteria, amylase, and an enzyme for fermented soybean paste are added to and mixed with a wild immature papaya fruit naturally growing in the ground where ultraviolet radiation is strong. The mixture is then left at rest and fermented. Then mixture is added and blended with glucose and dried. The resultant product is left at rest and aged for a long term, such as at least six months, thereby producing the fermented papaya product that has the hydroxyl radical-erasing activity of 50-4,000 μg/mL when described as an IC50 value and the singlet oxygen-erasing activity of 40-3,000 μg/mL when described as an IC50 value. The fermented papaya product-containing soap is produced by containing 1.0-10.0 wt.% of the fermented papaya product.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative-hypnotic drugs. Because some of the important adverse effects of sedative-hypnotics appear to be dose related (see Precautions and Dosage and Administration), it is important to use the smallest possible effective dose, especially in the elderly.

Complex behaviors such as "sleep-driving" (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported. These events can occur in sedative-hypnotic-naïve as well as in sedative-hypnotic-experienced persons. Although behaviors such as sleep-driving may occur with sedative-hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with sedative-hypnotics appears to increase the risk of such behaviors, as does the use of sedative-hypnotics at doses exceeding the maximum recommended dose. Due to the risk to the patient and the community, discontinuation of sedative-hypnotics should be strongly considered for patients who report a "sleep-driving" episode.

Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.
Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
BACKGROUND: Little studies were conducted to assess the prevalence of stress urinary incontinence among Palestinian women. This study was conducted to determine the prevalence of stress urinary incontinence symptoms, their impact on the quality of life, and the risk factors that were associated with stress incontinence symptoms among Palestinian women.
METHODS: This study was conducted in a cross-sectional design from 2023 to 2024. The data were collected through an interviewer-administered questionnaire. The questionnaire collected the demographic and health characteristics of the women. Additionally, the questionnaire also contained the PRAFAB questionnaire (PRAFAB-Q). Moreover, the questionnaire included the Assessment of Quality of Life (AQoL)-8D scale.
RESULTS: Data were collected from 386 Palestinian women (response rate = 85.8%). The mean age of women in this study was 37.1 ± 14.7 years. In this study, 104 (26.9%) reported stress urinary incontinence symptoms. Of the women, 102 (26.4%) reported urinary leakage during coughing, 100 (25.9%) reported urinary leakage during sneezing, and 94 (24.4%) reported urinary leakage during laughing. The women who had a family history of stress incontinence were 2.5-fold (95% CI: 1.2-5.2) more likely to have stress incontinence symptoms compared to the women who did not have a family history of stress incontinence. Similarly, the women who were overweight/obese were 2.0-fold (95% CI: 1.1-3.7) more likely to have stress incontinence symptoms compared to the women who were underweight or had a normal weight. PRAFAB-Q scores were predicted by place of residence, family history of stress incontinence, and being recruited from a hospital.
CONCLUSION: The study reported a high prevalence of stress urinary incontinence and identified the risk factors that were associated with stress incontinence symptoms among Palestinian women. The findings showed that the intensity of stress urinary incontinence symptoms was associated with deteriorated quality of life of the affected women. These findings could be used by urologists, gynecologists, obstetricians, and other healthcare providers caring for women to design ways to reduce the burden of stress urinary incontinence among Palestinian women and improve their quality of life.
Objective: To demonstrate the superiority of a strategy of platelet monitoring (Monitoring Arm) with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low responders as compared to a more conventional strategy of a fixed dose of 5 mg to every patient without monitoring (Conventional Arm).Rationale: Prasugrel 10 mg is superior to clopidogrel in patients with acute coronary syndrome treated by percutaneous coronary intervention, reducing significantly the rates of ischemic events. Elderly patients appear to be at higher risk of bleeding events and pharmacokinetic data suggests that elderly patients are exposed to a higher concentration of the active metabolite of prasugrel. A reduced dose of 5 mg of prasugrel is therefore proposed to these patients to limit the risk of bleeding. On the other hand, the elderly have also a higher ischemic risk and higher levels of platelet aggregation under treatment than younger patients and may deserve stronger protection from antiplatelet therapy. Platelet function testing appears to be of particular interest in patients at high risk of both ischemic and bleeding events like the elderly. Too intense platelet inhibition may expose the elderly patients to an excessive bleeding risk. Too low platelet inhibition may expose them to recurrent cardiovascular ischemic events. The possibility of bedside monitoring of oral antiplatelet therapy offers the opportunity of tailoring prasugrel therapy in elderly patients to optimize their risk/benefit ratio. Such strategy has never been evaluated in a randomized and adequately powered study. Population: Acute coronary syndrome (STEMI and NSTEMI) treated by PCI-stent (bare metal stent or drug eluting stent) in patients aged 75 ≥ year. Methods: Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR). Patients will be monitored again 2 weeks later, only if they do not meet the Verifynow P2Y12 targets at the first assessment. Primary endpoint net clinical benefit at 12 months:Composite of Cardiovascular death, myocardial infarction, stroke, urgent revascularisation, stent thrombosis and bleedings according to the BARC definitions (type 2, 3 or 5) Centers: Approximately 40 French high volume PCI centers
Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months. Oral Mycophenolate mofetil 0.75g bid for 6 months.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to novel substituted isoxazoles of the general formulas (I)  , (II)  , (III)  , (IV)  , (V)   where R 1  is taken among lower alkyl, carboxyalkyl, alkoxycarbonyl, aminocarbonyl, aminocarbonylalkyl and others; R 2  is taken among alkylsulfonyl, hydroxysulfonyl and aminosulfonyl; R 3  is taken among phenyl or 6-membered heterocycle containing one nitrogen atom being phenyl can be optionally substituted with one or more radicals taken independently among alkyl, cyano-group, halogenalkyl, hydroxyalkyl and others under condition that R 2  means aminosulfonyl in the case if R 2  as a substituted phenyl radical is at 3- position of isoxazole; R 4  is taken among lower alkyl, hydroxyl, carboxyl, halogen atom, lower carboxyalkyl and others; R 5  is taken among methyl, hydroxy-group and amino-group; R 6  is taken among phenyl or 6-membered heterocycle containing one nitrogen atom being phenyl can be optionally substituted with one or more radicals taken independently among lower alkylsulfinyl, lower alkyl, cyano-group, lower halogen-alkyl and others; R 7  is taken among lower alkyl, hydroxyl, carboxyl, halogen atom, lower carboxyl and others; R 8  means one or more radicals taken independently among hydrogen atom, lower alkylsulfinyl, lower alkyl, cyano-group, lower halogen alkyl and others; R 9  is taken among alkyl, lower carboxyalkyl, lower alkoxycarbonylalkyl and others; R 10  means one or more radicals taken independently among hydrogen atom, lower alkyl, halogen atom, lower alkoxy-group; R 11  is taken among methyl and amino-group; R 12  means one or more radicals taken independently among hydrogen atom, lower alkyl, halogen atom, lower halogenalkyl, lower alkoxy-group; R 13  is taken among lower alkyl, lower carboxyalkyl, lower alkoxycarbonylalkyl, lower aralkyl; R 14  is taken among methyl and amino-group; and their pharmaceutically acceptable salts. Invention relates also to pharmaceutical composition eliciting activity inhibiting cyclooxygenase-2 activity containing compound of the formula (I) or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier. Invention relates also to method of suppression of states associated with enhanced activity of cyclooxygenase-2, inflammations and associated disorders that involves administration of compound of the formula (I) or its pharmaceutically acceptable salt in patient with indicated disorder or susceptible to this disorder in therapeutically effective dose. Invention provides the development of novel substituted isoxazoles. EFFECT: improved method of treatment, valuable medicinal properties of compounds. 23 cl, 2 tbl
INTRODUCTION AND OBJECTIVES: The increasing incidence of ischemic heart disease is a serious threat to human health. Increased CASC15, a long non-coding RNA, has been shown to adversely affect cardiac muscle. The objective of this paper was to explore the effect of CASC15 on a cell model of myocardial infarction and its possible mechanism.
METHODS: H9c2 cells were selected to establish the myocardial infarction model through hypoxia/reoxygenation (H/R) treatment. The expression of CASC15 was attenuated by cell transfection in vitro. The level of CASC15 was detected by RT-qPCR. Cell viability was detected by CCK-8 assay, and cell apoptosis was assessed by flow cytometry. The content of MDA and the activity of SOD and GSH-Px were measured by ELISA. Luciferase reporter gene assay was used to determine the relationship between CASC15 and miRNA.
RESULTS: CASC15 expression was increased in H/R-treated H9c2 cells. Overexpression of CASC15 adversely affected cell viability and promoted H/R-induced oxidative stress. Inhibition of CASC15 promoted cell viability and suppressed cell apoptosis and oxidative stress damage. Additionally, luciferase reporter gene assay confirmed the targeting relationship between CASC15 and miR-542-3p, and attenuating CASC15 expression enhanced the level of miR-542-3p. Reduction of miR-542-3p weakened the viability of the H/R cell model, increased apoptosis, and enhanced oxidative stress damage.
CONCLUSION: This study suggests that overexpression of CASC15 may inhibit the viability of H9c2 cells, promote apoptosis and induce oxidative stress through targeted regulation of miR-542-3p expression.
Objective: To evaluate the effect of prucalopride and buspirone, compared to placebo, in the prevention of gastric pain crises, in a double-blind clinical trial of a single patient. Methods: Female, 35 years old, with signed consent to participate in the study, received 15 capsules to take 1 capsule 60 minutes before ingesting 200 ml of red wine at home (≈20 grams of alcohol), twice a week, according to her routine food, totaling 15 meals. Thus, the experimental phase lasted about eight weeks. The 15 capsules contain placebo (5 capsules), prucalopride 2 mg (5 capsules) or buspirone 10 mg (5 capsules), prepared by a specialized pharmacy in such a way that their physical characteristics do not allow the identification of which agent is being administered, neither by the patient nor the investigator controlling the trial (double-blind). The aforementioned pharmacy generated a code for each pill, randomly, and provided a sealed list with the 15 codes and their respective drugs, for disclosure after the end of the study. The patient was instructed to record in a standardized diary the occurrence of pain crises after the wine challenge, as well as their duration and intensity (Likert 0 to 10: maximum pain), and accompanying symptoms. The patient was asked to contact the researchers directly (WhatsApp) throughout the trial, to clarify any doubts or need for some assistance due to the occurrence of symptoms related to the study. The study statistics will be descriptive in terms of pain events, and the effect of the drugs will be evaluated in a statistical model suitable for the N-of-1 trial. Prucalopride is a 5-HT4 receptor agonist that accelerates gastric emptying, while buspirone is a 5-HT1A receptor agonist that enhances gastric accommodation function. The presumed pathophysiology underlying the patient's pain is retention of wine in the gastric lumen, causing pain. Stimulating gastric emptying with prucalopride or increasing the accommodation of the gastric fundus with buspirone could prevent or alleviate the pain crisis.
Participants will be connected to the MiniMed 780G AHCL system for the 12 months study period. This group will have two additional visits to allow for patients to be trained on the AHCL system.
The utility model relates to a soft capsule of eucommia ulmoides seed oil, which is a healthy health care product. The utility model comprises an edible casing of the soft capsule. The utility model is characterized in that 0.35 g to 0.5 g of eucommia ulmoides seed oil is sealed in the soft capsule. The eucommia ulmoides seed oil comprises from 60% to 70% alpha-linoleic acid, the acid value is less than 1.8, the iodine value is from 180 to 255, the saponification value is from 180 to 200, and the content of VE of 100 grams of the eucommia ulmoides seed oil is more than 30 grams. The utility model has the advantages that after the eucommia ulmoides seed oil is added with antioxidant and is encapsulated in the soft capsule in a shaping and quantitative way, the rancidity and the oxidation can be efficiently suppressed, and the shelf life can be extended to be more than two years. The capsule is convenient in carrying, and the utility model can be accurately and quantitatively taken.
The invention discloses pure traditional Chinese medicine powder special for traumas. The pure traditional Chinese medicine powder consists of the following raw materials by weight: 100-200g of pearl, 100-200g of gypsum, 5-15g of yellow lead powder and 5-15g of borneol. The pure traditional Chinese medicine powder disclosed by the invention has the effects of clearing and activating channels and collaterals, promoting blood circulation to dispel blood stasis, killing insects and bacteria, reducing swelling to relieve pain, clearing away heat and toxic materials, and removing necrotic tissues to promote granulation, and has unique and significant curative effects on diseases of burns and scalds, wounds by knives or axes, bleeding wounds with skin cut open and flesh torn, trauma infection and the like. The pure traditional Chinese medicine powder disclosed by the invention is quick in drug effect, can be used for treating multiple diseases with one formula, belongs to medicines for the traumas, and cannot be taken orally. The pure traditional Chinese medicine powder disclosed by the invention is convenient to use, high in quality, low in price, and suitable common people both the young and the old, can treat both symptoms and root causes, and does not have toxic or side effects. By virtue of years of clinical practices, food taboos are not found, and paradoxical reactions and phenomena are not found either.